ArticleNPJ precision oncology2026
A comprehensive foundation model for generalizable cytogenetics in precision oncology with CHROMA.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence in oncology: linking biological discovery to clinical utility.Molecular cancer · 2026Review
- Multimodal AI reading of genetic complexity and residual marrow composition in acute promyelocytic leukemia.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Automated cytogenomic analysis has long been limited by narrow task scope, high annotation demands, and poor robustness to real-world complexity. Here, we introduce CHROMA, the first single-chromosome foundation model for cytogenomics that enables comprehensive, cell-level detection of a wide spectrum of chromosomal abnormalities-including both common and ultra-rare types-in a single, unified framework. Pre-trained on over 4 million chromosomal images from more than 84,000 specimens using self-supervised learning, CHROMA achieves robust and comprehensive detection of numerical and structural abnormalities across diverse classes, dramatically reducing expert annotation workload by 40% through efficient label utilization. The model maintains state-of-the-art accuracy even under highly imbalanced data and challenging imaging conditions, supporting reliable deployment as a risk-aware screening and triage tool, particularly in settings with limited expert availability. An integrated risk-control strategy further ensures safe application by automatically flagging uncertain or rare cases for expert review. By bridging foundational AI advances with real-world clinical needs, CHROMA paves the way for scalable, accessible, and precise cytogenomic analysis in both advanced and underserved healthcare environments.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.